Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages
Science Advances · 2025
DOI: 10.1126/sciadv.adu3344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Caroline K Page und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA. Hauptthemen laut MEDLINE: Neuraminidase, Antibodies, Viral, Cross Protection, Influenza B virus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.
Abstract (Originalsprache)
The two influenza B virus (FLUBV) lineages have continuously diverged from each other since the 1980s, with recent (post-2015) viruses exhibiting accelerated evolutionary rates. Emerging data from human studies and epidemiological models suggest that increased divergence in contemporary viruses may drive differential cross-protection, where infection with Yamagata lineage viruses provides limited immunity against Victoria lineage viruses. Here, we developed animal models to investigate the mechanisms behind asymmetric cross-protection between contemporary FLUBV lineages. Our results show that contemporary Victoria immunity provides robust cross-protection against the Yamagata lineage, whereas Yamagata immunity offers limited protection against the Victoria lineage. This differential cross-protection is driven by Victoria-elicited neuraminidase (NA)–specific antibodies, which show cross-lineage reactivity, unlike those from Yamagata infections. These findings identify a phenomenon in contemporary FLUBV that may help explain the recent disappearance of the Yamagata lineage from circulation, highlighting the crucial role of targeting NA in vaccination strategies to enhance cross-lineage FLUBV protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.
- Center for Influenza Disease and Emergence Response (CIDER), University of Georgia, Athens, GA 30602, USA.
- Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
- The Shraga Segal Department of Microbiology and Immunology, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
- National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
ORCID-Profile: Caroline K Page, Justin D Shepard, Sean D Ray, James A Ferguson, Julianna Han, Joel C Jacob, Dawne K Rowe-Haas, Jasmine Y Akinpelu, Lilach M Friedman, Tomer Hertz, Andrew B Ward, Stephen M Tompkins
Förderung
- NIH HHS
Zitieren
APA
Page, C. K., Shepard, J. D., Ray, S. D., Ferguson, J. A., Rodriguez, A. J., Han, J., Jacob, J. C., Rowe-Haas, D. K., Akinpelu, J. Y., Friedman, L. M., Hertz, T., Ward, A. B., & Tompkins, S. M. (2025). Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages. Science Advances. https://doi.org/10.1126/sciadv.adu3344
Vancouver
Page CK, Shepard JD, Ray SD, Ferguson JA, Rodriguez AJ, Han J, et al. Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages. Science Advances. 2025. doi:10.1126/sciadv.adu3344
BibTeX
@article{Page2025,
author = {Page, Caroline K and Shepard, Justin D and Ray, Sean D and Ferguson, James A and Rodriguez, Alesandra J and Han, Julianna and Jacob, Joel C and Rowe-Haas, Dawne K and Akinpelu, Jasmine Y and Friedman, Lilach M and Hertz, Tomer and Ward, Andrew B and Tompkins, Stephen M},
title = {Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adu3344}
}
EUVIMED